North Burnett Regional Council hands down Queenland's biggest rate increase
The financially struggling North Burnett Regional Council raised general rates by 25 per cent in its $69-million, 2025-26 budget delivered on Monday morning, surpassing Townsville City Council's recent 20 per cent increase for some owner-occupiers.
All separate charges, such as sewerage, water and waste, as well as and levies for local disasters, natural resource and landfill management have increased by 19 per cent.
Mayor Les Hotz said the increase – which would amount to more than $800 per year for residential ratepayers – was necessary to pay for council's utilities and services without relying on additional government grants.
He said the added revenue from the increased rates and fees would shave about $2.6m off the council's deficit and bring it down to about $8m at the end of this financial year.
"We're just trying to meet the costs without having to reach out and ask our state and federal government to assist," he said.
"I'm sympathetic toward the the ratepayer that is struggling, the pensioner and those that do not have work.
Pensioner Colin Boot was in the public gallery for the budget meeting at Gayndah Community Hall.
The 81-year-old Gayndah resident said he would have to cut down on other expenses.
"I just can't see where we're going to get that extra money … the only thing I can see is [cancelling] insurance," Mr Boot said.
"Ten per cent — we would have coped with it somehow, but 25 per cent?"
Resident and former councillor Dael Giddens said families would likely cut back on after-school activities.
"You might have had the kids playing cricket and soccer and doing swimming," she said.
The North Burnett region is one of the largest in the state, covering almost 20,000 square kilometres and a total of more than 4,800km of sealed and unsealed roads owned by the council and the state government.
Chief executive Craig Matheson said council's approach to the budget was guided by previous community consultation that "unequivocally showed" that residents wanted existing services retained.
"It was a challenge, but we knew without a doubt what the community wanted," he said.
Mr Matheson said costs had increased by 10 per cent in recent years but the ratepayer base of 6,323 properties had only grown by one per cent in the last decade.
First-term councillor Trina Vaughn voted against the budget because of the added burden it would place on ratepayers already struggling with the cost of living.
"I've spoken with people who are going without medication because they just can't make ends meet," she said.
"It's definitely a problem that has been imposed on us by the current climate and it's not just a North Burnett Regional Council problem — it is Australia-wide."
Deputy Mayor Melinda Jones voted against the budget but was in favour of raising fees and charges.
"We've weathered fires and floods and now we need to weather something else — the cost of catching up," she said.
The budget's long-term forecast indicates that the council's cash reserves will dwindle to less than one month's operating expenditure before rising above the target of four months by 2032-33.
Local Government Association of Queensland (LGAQ) chief executive Alison Smith said the rate increase showed councils had "reached a tipping point" beyond which they could no longer pay for community services.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
41 minutes ago
- ABC News
Synergy to repay $2.29 million after overcharging Centrelink customers for electricity
Western Australia's state-owned power utility overcharged thousands of vulnerable customers over more than a decade, according to a new report. WA's economic watchdog has been probing issues related to customers paying their power bills using Centrepay, which allows for automatic deductions from Centrelink support payments. The Economic Regulation Authority (ERA) found in up to 2,845 cases, the utility had continued to take money from customers' Centrelink payments after they had closed their Synergy accounts. It believes those issues date back to 2009 at a total cost of $2.29 million. Changes to the code of conduct under which Synergy operates means it can only be ordered to repay 459 customers who were affected since February 2023 and are collectively owed $239,250. But Synergy has indicated all customers will be reimbursed. "This is a particularly concerning breach, given Synergy's position as the largest retailer in the state and the vulnerability of this cohort of customers that are receiving Centrelink support," ERA chair Steve Edwell said in a statement. "We would expect Synergy to have systems in place that would have identified these payments accruing in closed accounts — with around 1,000 customers owed more than $500." Synergy is government-owned and WA's largest electricity generator and gas retailer. It provides 52 per cent of electricity to households and businesses in the South West Interconnected System. The system covers Perth and extends from Kalbarri in the north, east to Kalgoorlie and south to Albany. Source: Synergy website In a statement, recently appointed Synergy CEO Kurt Baker apologised to customers affected by the issue, saying "they were let down". The ERA said the utility had been contacting affected customers since April, with around 30 per cent of the money owed paid back so far. "Our systems are complex and identifying impacted customers took some time," Mr Baker said in a statement. "As soon as possible after Centrepay overpayments were confirmed we took steps to resolve the issue and are continuing to do so." The Synergy chief indicated all affected customers dating back to 2009 would be paid back, with about half of all refunds totalling $250 or less. "We also expect Synergy to make changes to its customer management systems so that these sorts of payments are automatically flagged and dealt with," Mr Edwell said. Mr Baker said a "thorough review" would be undertaken to make those changes. "This review will identify any further overpayments on inactive accounts so that we can make refunds," he said. Synergy has been ordered to make those changes and make "best endeavours" to repay all 459 customers by the end of November. The ERA said while six other electricity and gas retailers in the state also charge customers via Centrepay, it did not believe the issue was widespread.

ABC News
41 minutes ago
- ABC News
Racist abuse of Nasiah Wanganeen-Milera, Jase Burgoyne condemned by AFL, St Kilda and Port Adelaide
St Kilda star Nasiah Wanganeen-Milera and Port Adelaide's Jase Burgoyne are the latest AFL players to call out racist abuse from faceless trolls online. The pair shared details of a series of messages they received via social media on Sunday night. The Saints and Power strongly condemned the messages, both clubs confirming on Monday they are working with the AFL Integrity Unit to identify those responsible. Wanganeen-Milera received messages from an anonymous account after the Saints' narrow five-point loss to Sydney. The messages appeared to be related to betting on Wanganeen-Milera's disposal tally. The 22-year-old playmaker had 24 disposals under close attention from Swans tagger James Jordon. In response to the abuse, Wanganeen-Milera posted: "Over a game of football! Hero mate." He received support from Saints teammate Liam Stocker, who reposted Wanganeen-Milera's story with the message: "Get a grip. Pissant. Put your name on it you donkey." "As a club we do not accept racist behaviour of any kind," Saints chief executive Carl Dilena said in a statement. "These comments are abhorrent and have no place in our game or our community. "Beyond Nasiah's talent on the field, he is a proud Kokatha and Narangga man who deserves to work and live free from this type of abuse. "St Kilda Football Club stands firmly with Nasiah, his family and all First Nations people, and we remain committed to fostering a safe and inclusive environment for everyone." Burgoyne also shared an image of messages he received, which also targeted his family, after Port's 26-point win over West Coast. The 21-year-old posted the screenshot with a clown emoji seemingly directed at the troll. "Such abuse is reprehensible and will not, and should not, be tolerated," Port Adelaide said in a statement. "The club has advised the AFL integrity department and we look forward to working closely with the AFL to identify those responsible and sanction appropriately. "We also encourage people who witness or experience online abuse to report and highlight it to the social media platforms on which it appears." Port Adelaide also called on governments to demand accountability from social media organisations. "Platforms need to take accountability and action against these abusers," the club said. The AFL and AFL Players Association have repeatedly condemned online racial abuse of players in recent years. AFL chief executive Andrew Dillon acknowledged the courage of Wanganeen-Milera and Burgoyne in calling out the "unacceptable" racist comments, and offered the league's support to the pair. "To hide behind a fake account is cowardly and I want the people that have created these online accounts and racially abused our players to know that our game does not want you," Dillon said. "Real fans don't racially abuse players. "We have been clear that there is absolutely no place for this behaviour in our sport and in society. "Racism is never acceptable and these incidents demonstrate there is so much more work to be done." AAP

News.com.au
an hour ago
- News.com.au
Health Check: Imugene goes to the well after reporting more blood cancer ‘cures'
Imugene reports two more 'complete responders' in its cell therapy trial Clever Culture Systems shares surge 17% on deal with Big Pharma Novo Nordisk Compumedics shares vault 24% after full-year update Imugene (ASX:IMU) will forge ahead with a planned pivotal US trial for its blood cancer therapy Azer-cel, having recorded more 'complete responses' in its phase 1b study. There's also the matter of cash, with Imugene shares this morning entering trading halt amidst a capital raising reportedly targeting $35 million. The trial is testing the company's CD-19 Car-T therapy on patients with relapsed diffuse large B-cell lymphoma. This is an especially aggressive blood cancer and these patients have failed multiple therapies. The company reports that of five further patients evaluated, two showed a 'complete response'. A complete response is the disappearance of all cancer signs – a.k.a. a cure. A further five showed a 'partial response' – at least a 50% cancer cell reduction. This takes the total number of complete responses to six and partial responses to three, out of 12 patients. The effect has endured for at least 60 days, with the first patient treated remaining cancer free at the 15-month mark. 'Allo 'allo, we're on to something If approved, Azer-cel would be the first off-the-shelf Car-T therapy using donor cells rather than the patients' own material. This is the allogeneic (allo), as opposed to autologous, method. Car-T therapies involve taking T-cells out of blood and tricking them up with agents that bolster their cancer-busting abilities. They are then re-introduced into the bloodstream. The re-engineered cells pursue a target, in this case the CD-19 protein expressed by blood cancers. Next stop: FDA The ongoing study is being carried out at 13 US sites and the first of five planned local sites. The company in February treated the first Australian participant, at Sydney's Royal Prince Alfred Hospital. The subjects were dosed with Azercel, combined alongside chemotherapy and the immunity agent interleukin 2. Imugene plans to meet with the US Food & Drug Administration (FDA) in the December quarter, to discuss a pivotal registration study. As of the end of March, Imugene held cash of $36 million. Drug development is hideously expensive and the last raising is never the final one, and what better time to go to the well than after positive clinical results? Imugene raised $53 million in 2023 and $80 million in 2020 and this year entered into a $20 million convertible note issue. Imugene shares have lost 68% year to date, adjusting for a share consolidation that reduced its 7.46 billion shares on issue to a more respectable 219 million. Clever Culture bulks up with fat-busting drug maker Clever Culture Systems (ASX:CC5) has signed up Big Pharma Novo Nordisk for one of its automated agar plate reading devices to monitor ultra-clean drug making facilities. The maker of the weight loss and diabetes drugs Ozempic and Wegovy, Novo Nordisk will acquire and appraise one of Clever Culture's AI-enabled device APAS Independence units, in view of a full global rollout across its facilities. The AI-enabled APAS Independence devices automatically read the hundreds of agar plates required to ensure that pathogens don't enter aseptic facilities. The units can manage 200 plates per hour, freeing up microbiologists to focus on the minority of plates that read positive. To date Clever Culture has focused on 90 millimetre 'settle' plates that are left open, to absorb any nasties in the room. A tweaked APAS also will read 55mm 'contact' plates, which are dabbed on surfaces, such as a gown or gloved fingertips. Nova Nordisk will assess both settle and contact plate modules. Courting Big Pharma Clever Culture CEO Brent Barnes says the 'milestone' deal aligns with the company's focus on the big drug makers, most of which have centres to appraise new products. To date Clever Culture also sold the devices to Astrazeneca, Bristol Myers Squibb and Thermo Fisher Pharma Services, while a fifth drug maker recently completed a 'successful evaluation'. The five drug makers on the books represent a sales opportunity of between 60 to 80 units. At last count the company had 13 APAS devices in the field, with foundation client Astrazeneca accounting for nine of them. The company cites a 'pipeline' of 40 customers, representing upfront revenue of about $75 million and $15 million of recurring revenue. The APAS unit sells for US$350,000, but Clever Culture then derives ongoing income from an annual software licence of US$30,000 (rising to US$50,000 with the contact plate modality). There's also an annual hardware maintenance fee of $US15,000-25,000. The FDA approved APAS Independence in May 2019 and European regulators followed suit in September 2021. There's no snoozing at Compumedics Sleep and neurological testing house Compumedics (ASX:CMP) has reported record revenue of $51 million for the year to June 2025, up 4%. What's more, the company has returned to profitability, with underlying earnings of $3 million. Compumedics also reports record sales orders of $63.4 million, up 22%. The key driving force was the growth of the US sleep diagnostics arm, up 39% to $53 million. The company also affirmed current year guidance of revenue of at least $70 million and underlying earnings of around $9 million. 'This result reflects the step-change underway at Compumedics,' founder and executive chairman Dr David Burton says. "We are building a more predictable, higher-margin business model and seeing consistent revenue growth, expanding margins and meaningful traction in the US." Proteomics ain't horsing around In time for the spring racing season, Proteomics International Laboratories (ASX:PIQ) says its oxidative stress test Oxidx can detect muscle damage in thoroughbreds. As published in the peer-reviewed journal Veterinary Medicine and Science, the 'groundbreaking' results show Oxidx can identify and assess recovery from exercise-induced damage. The study was based on 34 nags. The company says up to 85% of thoroughbreds sustain at least one injury during their racing seasons, potentially because of undetected muscle injuries. 'Oxidative stress has been implicated in many disease and injury states, with levels often reflective of a person or animal's health condition.' Via its 66% owned OxiDx Pty Ltd, Proteomics plans to launch Oxidx locally in the current half. Proteomics has a commercialised diabetic kidney disease diagnosis and plans to launch an endometriosis assay locally in the current quarter. No pay, no worries says Pacific Edge Pacific Edge (ASX:PEB) reports resilient demand for its bladder cancer diagnostic in the US, despite authorities withdrawing reimbursement coverage. The Kiwi-based company said US June quarter test volumes declined 12% to 5717, relative to the March quarter. Asia Pacific volumes – including those derived here – rose 8.8% to 1183. The company attributed the decline mainly to customers moving to its Cxbladder Triage product, from the discontinued Cxbladder Detect. Cxbladder Triage tests accounted for 77% of total US assays, up from 22% in the March quarter. Pacific Edge also said it had held positive discussions with Novitas, its US Medicare gatekeeper, about reinstating coverage. This was 'based on evidence not considered in the review that led to the non-coverage decision.'